Madrigal Pharmaceuticals Inc. (MDGL) |
|
109.04 -4.96 (-4.35%)
|
01-17 17:03 |
|
Open: |
112.72 |
Pre. Close: |
114 |
|
High:
|
115.93 |
Low:
|
108.605 |
|
Volume:
|
147,739 |
Market Cap:
|
1,686M |
|
|
|
|
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
116.054 - 116.72 |
116.72 - 117.321 |
|
Low:
|
107.147 - 107.84 |
107.84 - 108.466 |
|
Close:
|
108.044 - 109.154 |
109.154 - 110.155 |
|
Technical analysis |
as of: 2021-01-15 4:42:57 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 138.46 One year: 148.13 |
| Support: |
Support1: 105.16 Support2: 87.49 |
| Resistance: |
Resistance1: 118.55 Resistance2: 126.82 |
| Pivot: |
112.44 |
| Moving Average: |
MA(5): 112.53 MA(20): 113.90
MA(100): 118.39  MA(250): 104.48 |
| MACD: |
MACD(12,26): -1.87 Signal(9): -1.90 |
| Stochastic oscillator: |
%K(14,3): 39.26 %D(3): 42.94 |
| RSI: |
RSI(14): 39.32 |
| 52-week: |
High: 137.28 Low: 56.82 Change(%): 29.9 |
| Average Vol(K): |
3-Month: 14342 10-Days: 13066 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.MDGL has closed above bottom band by 22.2%. Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 16 Jan 2021
Analysts Anticipate Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Will Post Earnings of -$3.82 Per Share - MarketBeat
Wed, 13 Jan 2021
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Lowered by Zacks Investment Research - MarketBeat
Tue, 12 Jan 2021
B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com - Investing.com
Tue, 05 Jan 2021
Madrigal Pharmaceuticals - Consensus Indicates Potential 43.7% Upside - DirectorsTalk Interviews
Fri, 27 Nov 2020
Madrigal Pharmaceuticals: A Look At The Early MAESTRO Trial Data - Seeking Alpha
Fri, 13 Nov 2020
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
15 |
| Shares Float (M) |
7 |
|
% Held by Insiders
|
19.47 |
|
% Held by Institutions
|
93.86 |
|
Shares Short (K)
|
2,440 |
|
Shares Short P. Month (K)
|
2,370 |
Stock Financials |
|
EPS
|
-11.070 |
|
EPS Est This Year
|
-2.670 |
|
EPS Est Next Year
|
-3.560 |
|
Book Value (p.s.)
|
18.730 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-27.8 |
|
Return on Equity (ttm)
|
-46.8 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-11.421 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-115 |
|
Levered Free Cash Flow (M)
|
-57 |
Stock Valuations |
|
PE Ratio
|
-9.85 |
|
PEG Ratio
|
|
|
Price to Book value
|
5.82 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-14.68 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
